Alnylam Pharmaceuticals (ALNY) Non-Current Deffered Revenue (2009 - 2024)

Alnylam Pharmaceuticals (ALNY) has reported Non-Current Deffered Revenue for 16 consecutive years, with $1.0 million the latest figure, recorded in Q3 2024.

• For the quarter ending Q3 2024, Non-Current Deffered Revenue fell 99.48% year-over-year to $1.0 million; the trailing twelve-month figure through Sep 2024 stood at $1.0 million (down 99.48% YoY), and the FY2023 full-year result was $188.2 million, down 2.9% from the prior year.
• Non-Current Deffered Revenue eased to $1.0 million in Q3 2024 per ALNY's latest filing, from $2.4 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $306.1 million in Q1 2020 and bottomed at $1.0 million in Q3 2024.
• Historically, Non-Current Deffered Revenue has averaged $180.9 million across 5 years, with a median of $191.3 million in 2023.
• The sharpest annual moves came in 2020 and 2024: Non-Current Deffered Revenue surged 63942.68% in 2020, then plunged 99.48% in 2024.
• Over 5 years, Non-Current Deffered Revenue stood at $225.1 million in 2020, then sank by 32.31% to $152.4 million in 2021, then increased by 27.19% to $193.8 million in 2022, then retreated by 2.9% to $188.2 million in 2023, then sank by 99.46% to $1.0 million in 2024.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $1.0 million, $2.4 million, and $185.5 million for Q3 2024, Q2 2024, and Q1 2024 respectively.